Biotech catalyst calendar
Clinical trials led by listed companies, by the completion date the sponsor registered on ClinicalTrials.gov, soonest first, from today. Most future dates are the sponsor's estimate and can move.
- Completion LockedNo phase registeredNCT06618612A Study to Evaluate the Efficacy of a Purified Native Type 1 Collagen Extracellular Matrix With Polyhexamethylene Biguanide...Organogenesis · Diabetic Foot UlcerRecruitingORGOLead
- Enrollment
- Locked
- Primary completion
- Aug 19, 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedNo phase registeredNCT07356323A Prospective, Single-arm, Trial to Determine Contamination Rates When Using an Antibacterial Incise Drape During Orthopedic SurgerySolventum US LLC · Arthroplasty Replacement, KneeRecruitingSOLVLead
- Enrollment
- Locked
- Primary completion
- Nov 20, 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedPhase 1NCT07820891A Trial in Healthy Participants to Assess Drug Interaction Potential of BGB-43395BeOne Medicines · Healthy Adult ParticipantsRecruitingONCLeadFTRECollaborator
- Enrollment
- Locked
- Primary completion
- Nov 22, 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedPhase 3NCT06693895A Study on the Safety of an Investigational Chickenpox Vaccine, When Given to Healthy Children, 12 to 15 Months of AgeGlaxoSmithKline · ChickenpoxRecruitingGSKLead
- Enrollment
- Locked
- Primary completion
- Nov 23, 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedNo phase registeredNCT07735793A Real-world Study in Participants With High-risk Non-Muscle-Invasive Bladder Cancer After Bacillus Calmette-Guérin Therapy in KoreaJanssen Korea, Ltd., Korea · Urinary Bladder NeoplasmsRecruitingJNJLead
- Enrollment
- Locked
- Primary completion
- Nov 23, 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedPhase 1/Phase 2NCT06267729Study of AZD0754 in Participants With Metastatic Prostate CancerAstraZeneca · Metastatic Prostate CancerRecruitingAZNLead
- Enrollment
- Locked
- Primary completion
- Nov 24, 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedNo phase registeredNCT06376097Lung Cancer Screening Program Using Low-dose Tomography and Metabolomic Evaluation in a Public Service.AstraZeneca · Lung CancerRecruitingAZNLead
- Enrollment
- Locked
- Primary completion
- Nov 29, 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedPhase 4NCT06501443LATAM LOWERS LDL-CNovartis Pharmaceuticals · HypercholesterolaemiaRecruitingNVSLead
- Enrollment
- Locked
- Primary completion
- Nov 27, 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedPhase 2NCT03175224APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid TumorsApollomics Inc. · Solid TumorsRecruitingAPLMLead
- Enrollment
- Locked
- Primary completion
- Mar 30, 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedNo phase registeredNCT06146660A Study to Assess the Safety of Mavacamten in Korean Patients With Symptomatic Obstructive Hypertrophic CardiomyopathyBristol-Myers Squibb · Obstructive Hypertrophic CardiomyopathyRecruitingBMYLead
- Enrollment
- Locked
- Primary completion
- Nov 30, 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedPhase 3NCT06734832Efficacy, Safety, and Immunogenicity of the Bivalent Inactivated Enterovirus Vaccine (Vero Cell)Sinovac Biotech Co., Ltd · Hand, Foot, and Mouth Disease(HFMD)RecruitingSVALead
- Enrollment
- Locked
- Primary completion
- Nov 30, 2025Sponsor estimate
- Interventions
- Locked
- Completion LockedPhase 2NCT06812078A Study of TAK-360 in Adults With Idiopathic HypersomniaTakeda · Idiopathic HypersomniaRecruitingTAKLead
- Enrollment
- Locked
- Primary completion
- Nov 30, 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedPhase 2NCT06952699A Study of TAK-360 in Adults With Narcolepsy Without Cataplexy (NT2)Takeda · Narcolepsy Type 2RecruitingTAKLead
- Enrollment
- Locked
- Primary completion
- Nov 30, 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedPhase 1NCT07005713A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple-Ascending Doses of Tacabrutideg...BeOne Medicines · Chronic Spontaneous UrticariaRecruitingONCLead
- Enrollment
- Locked
- Primary completion
- Nov 30, 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedNo phase registeredNCT07361276Observational Study That Will Evaluate Treatment Patterns in the Management of Hypertension in the Public Primary Care SystemAstraZeneca · HypertensionRecruitingAZNLead
- Enrollment
- Locked
- Primary completion
- Nov 30, 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedNo phase registeredNCT07457580Real-World Study of Patients With Type 1 Diabetes Treated With Teplizumab as Part of Managed Access Programs (MAPs)Sanofi · Type 1 DiabetesRecruitingSNYLead
- Enrollment
- Locked
- Primary completion
- Nov 30, 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedPhase 4NCT07681076Study to Assess Safety and Tolerability of KarXT With Administration of Antiemetics in Healthy VolunteersKaruna Therapeutics, Inc., a Bristol Myers Squibb company · Healthy VolunteersRecruitingBMYLead
- Enrollment
- Locked
- Primary completion
- Nov 30, 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedNo phase registeredNCT07889219Study on the Long-Term Persistence of Immunity Induced by Inactivated Hepatitis A VaccineSinovac Biotech Co., Ltd · Hepatitis ARecruitingSVALead
- Enrollment
- Locked
- Primary completion
- Nov 30, 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedNo phase registeredNCT04802395Real World Evidence Clinical Utility Study of KidneyIntelXRenalytix AI, Inc. · Chronic Kidney DiseasesRecruitingRNLXYLead
- Enrollment
- Locked
- Primary completion
- Dec 1, 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedNo phase registeredNCT06910306Alpha Radiation Emitters Device (DaRT) for the Treatment of Recurrent GlioblastomaAlpha Tau Medical LTD. · Recurrent GlioblastomaRecruitingDRTSLead
- Enrollment
- Locked
- Primary completion
- Nov 1, 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedPhase 3NCT07446439A Study to Evaluate Tradipitant on Treating Nausea and Vomiting Induced by GLP-1R Agonist UseVanda Pharmaceuticals · Nausea and VomitingRecruitingVNDALead
- Enrollment
- Locked
- Primary completion
- Dec 1, 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedNo phase registeredNCT07517250A Study on the Use of Canakinumab Among Familial Mediterranean Fever and Still's Disease PatientsNovartis Pharmaceuticals · Familial Mediterranean FeverRecruitingNVSLead
- Enrollment
- Locked
- Primary completion
- Dec 3, 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedPhase 3NCT07500506A Study to Learn About the Safety, Tolerability, and Immunogenicity of a Fifth Dose of 6-Valent OspA-Based Lyme Disease VaccinePfizer · Lyme DiseaseRecruitingPFELead
- Enrollment
- Locked
- Primary completion
- Dec 4, 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedPhase 1NCT07777133A Study to Evaluate the Metabolism, the Routes and Extent of Elimination, and Drug Levels of [14C]Navlimetostat (BMS-986504) in Healthy...Bristol-Myers Squibb · Healthy Female ParticipantsRecruitingBMYLead
- Enrollment
- Locked
- Primary completion
- Dec 5, 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedPhase 4NCT07884175A Study of Updated mRNA Seasonal Influenza VaccinesModernaTX, Inc. · Seasonal InfluenzaRecruitingMRNALead
- Enrollment
- Locked
- Primary completion
- Dec 7, 2026Sponsor estimate
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 25 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScannerShowing the first 25 trials. There are 15 more in this window; the full list is part of TrialScanner.
Unlock with TrialScannerHow to read this calendar
Completion dates as registered on ClinicalTrials.gov by the sponsor, for trials Signal8 links to a listed company. Most future dates are the sponsor's estimate and move. A completion date is when the last participant is measured, not when results are announced.
The window starts today. A date the sponsor registered to the day is listed when it falls inside the window; a date that has already passed is never listed as upcoming, even when the sponsor has not updated it yet. A date registered to the month only (shown as, say, Dec 2026) could be any day of that month, so it is listed only when the whole month falls inside the window. TrialScanner never adds a day the sponsor did not register.
By default the list shows trials where a listed company is the lead sponsor. Trials a listed company only collaborates on (as a partner, drug supplier or contract research organization) are added with the role filter, and every company is labelled Lead or Collaborator.
Free readers see the first 25 trials of any filter and windows up to 90 days, with the trial, phase, status, sponsor and primary completion. Enrollment, interventions, the start and completion dates, longer windows and later pages are part of the plan. See the methodology.